DBV Technologies (DBVT) Gains from Investment Securities (2020 - 2025)
DBV Technologies (DBVT) reported Gains from Investment Securities of $1.2 million for Q4 2025, up 83.48% year-over-year from $672000.0 in Q4 2024, and up 10375.0% on a QoQ basis from -$12000.0 in Q3 2025.
DBV Technologies (DBVT) has 6 years of Gains from Investment Securities data on file, last reported at $1.2 million in Q4 2025.
- Quarterly Gains from Investment Securities rose 83.48% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $719000.0 (up 242.38% YoY) and the FY2025 annual result came in at $219000.0, up 7200.0% from the prior year.
- Gains from Investment Securities climbed to $1.2 million in Q4 2025 per DBVT's latest filing, from -$12000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.2 million in Q4 2025 and bottomed at -$2.1 million in Q3 2021.
- The 5-year median for Gains from Investment Securities is $3000.0 (2022), against an average of -$30000.0.
- The widest annual swing landed in 2021, when Gains from Investment Securities surged 800.0%; it then slumped 6350.0% in 2025.
- Tracing DBVT's Gains from Investment Securities over 5 years: stood at $558000.0 in 2021, then sank by 99.28% to $4000.0 in 2022, then sank by 675.0% to -$23000.0 in 2023, then surged by 3021.74% to $672000.0 in 2024, then soared by 83.48% to $1.2 million in 2025.
- Per Business Quant, the three latest DBVT Gains from Investment Securities figures stand at $1.2 million (Q4 2025), -$12000.0 (Q3 2025), and -$502000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.23 Mn |
| Dec 31, 2025 | 1.23 Mn |
| Sep 30, 2025 | -12,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Jun 30, 2025 | -502,000.00 |
| Jun 30, 2025 | -502,000.00 |
| Mar 31, 2025 | -500,000.00 |
| Mar 31, 2025 | -500,000.00 |
| Dec 31, 2024 | 672,000.00 |
| Dec 31, 2024 | 672,000.00 |
| Sep 30, 2024 | -636,000.00 |
| Sep 30, 2024 | -636,000.00 |
| Jun 30, 2024 | -41,000.00 |
| Jun 30, 2024 | -41,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Jun 30, 2023 | -23,000.00 |
| Jun 30, 2023 | -23,000.00 |
| Dec 31, 2022 | 4,000.00 |
| Dec 31, 2022 | 4,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Dec 31, 2021 | 558,000.00 |
| Dec 31, 2021 | 558,000.00 |
| Sep 30, 2021 | -2.06 Mn |
| Sep 30, 2021 | -2.06 Mn |
| Jun 30, 2021 | 387,000.00 |
| Jun 30, 2021 | 387,000.00 |
| Mar 31, 2021 | 456,000.00 |
| Mar 31, 2021 | 456,000.00 |
| Dec 31, 2020 | 134,000.00 |
| Dec 31, 2020 | 134,000.00 |
| Sep 30, 2020 | -413,000.00 |
| Sep 30, 2020 | -413,000.00 |
| Jun 30, 2020 | 43,000.00 |
| Jun 30, 2020 | 43,000.00 |
| Mar 31, 2020 | -419,000.00 |
| Mar 31, 2020 | -419,000.00 |